There is a wide range of drugs and combinations under investigation and/or approved over the last decade to treat colorectal cancer (CRC), but the 5-year survival rate remains poor at stages II-IV. Therefore, new, moreefficient drugs still need to be developed that will hopefully be included in first-line therapy or overcome resistance when it appears, as part of second-or third-line treatments in the near future. In this study, we revealed that heat shock protein 90 (Hsp90) inhibitors have high therapeutic potential in CRC according to combinative analysis of NCBI's Gene Expression Omnibus (GEO) repository and chemical genomic database of Connectivity Map (CMap). We found that second generation Hsp90 inhibitor, NVP-AUY922, significantly downregulated the activities of a broad spectrum of kinases involved in regulating cell growth arrest and death of NVP-AUY922-sensitive CRC cells. To overcome NVP-AUY922-induced upregulation of survivin expression which causes drug insensitivity, we found that combining berberine (BBR), a herbal medicine with potency in inhibiting survivin expression, with NVP-AUY922 resulted in synergistic antiproliferative effects for NVP-AUY922-sensitive and -insensitive CRC cells. Furthermore, we demonstrated that treatment of NVP-AUY922-insensitive CRC cells with the combination of NVP-AUY922 and BBR caused cell growth arrest through inhibiting CDK4 expression and induction of microRNA-296-5p (miR-296-5p)-mediated suppression of Pin1-β-catenin-cyclin D1 signaling pathway. Finally, we found that the expression level of Hsp90 in tumor tissues of CRC was positively correlated with CDK4 and Pin1 expression levels. Taken together, these results indicate that combination of NVP-AUY922 and BBR therapy can inhibit multiple oncogenic signaling pathways of CRC.
Introduction
Colorectal cancer (CRC) is the third most common cancer, and the third leading cause of cancer deaths in Western countries [1] . The choice for treating early rectal cancer is complete local excision [2] . Although surgery is reported to cure approximately 50% of patients with CRC [3] , approximately 40% of patients who undergo the first curative surgery present with suspected recurrence in the initial 2 years of follow-up [1] . In addition, approximately 50-70% of patients with CRC are diagnosed at more-advanced stages [4] . For these patients with CRC at stages II and III, in addition to the surgical resection, adjuvant postoperative chemotherapy may provide an additional benefit by eradicating potentially existing micrometastases and reduce the risk of cancer relapse after surgery [2] .
Drug treatment for CRC has transitioned from single-agent chemotherapy to combination cytotoxic therapies and target-specific agents [5] , but the 5-year survival rate remains poor at stages II-IV despite recent advances in chemotherapy and targeted agents. Clearly, better and more-efficacious drugs are needed, and target-specific agents remain the future of cancer treatment.
Drugs that are most commonly used to treat advanced and metastatic CRC are fluorouracil (5-FU), capecitabine, irinotecan and oxaliplatin. These four compounds are the bases of standard treatments used in clinical practice [6] . In stage III disease, administration of adjuvant 5-FU for 6 months reduces the risk of death by 30% [6] . But, in the XELOXA study of oral capecitabine plus oxaliplatin versus 5-FU and folinic acid (for stage III disease), there was an insignificant 5-year benefit in overall survival [7] . These data and toxicity considerations imply that new drugs and new regimens are expected to improve the response of CRC to pharmacological treatments.
Gene expression profiling is used as a powerful tool for elucidating disease-specific molecular mechanisms and biological pathways [8] , predicting drug responses and resistance [9] and disease outcomes [10] , and discovering new targets [2] . Several studies used gene expression profiles of CRC tissues to predict a poor prognosis and determine patients at high risk of recurrence [11, 12] . There is yet no comprehensive CRC gene expression of a related application system that specializes in anticancer agents. A novel technique to discover potentially therapeutic chemicals through a collection of chemically induced gene expression profiles, the Connectivity Map (CMap), proposed by Lamb et al. [13, 14] , and recently validated by Sirota et al. [15] , demonstrated how integrating genome-wide gene expression data of drugs and diseases can be used for compound repositioning. Hence, the combination of a genome-wide expression database of CRC and chemical genomic database can identify potential therapeutic agents for CRC. In this study, we analyzed the genomic signature of human CRC tissues to find very strong positive connections with heat shock protein 90 (Hsp90) inhibitors for treating CRC. We demonstrated that the second generation Hsp90 inhibitor, NVP-AUY922, is a potent apoptosis inducer in CRC cell lines. Furthermore, we found that its combination with a traditional herbal medicine, berberine (BBR), inhibited NVP-AUY922-induced drug resistance of CRC cells.
Materials and methods

Chemicals, reagents, antibodies and expression construct
The drug 17-allylamino-demethoxy geldanamycin (17-AAG) and berberine (BBR) were purchased from Sigma (St. Louis, MO, USA). NVP-AUY922 was purchased from Selleck Chemicals LLC (Houston, TX, USA). These three compounds were prepared in 100% DMSO. Crystal violet, propidium iodide (PI), and DMSO were all obtained from Sigma (St. Louis, MO, USA). Small interfering (si)RNA targeting survivin messenger (m)RNA, control siRNA, and the RNAiMax transfection reagent were purchased from Invitrogen (Carlsbad, CA, USA). Rabbit antibodies against Hsp90, HSF-1, survivin, CDK4, poly(ADP-ribose) polymerase (PARP), Ser(P)2448-mTOR, mTOR, Thr(P)389-p70S6K, p70S6K, Ser(P)473-Akt, Thr(P)308-Akt, Akt, Thr(P)183/Tyr(P)185-JNK, and JNK were obtained from Cell Signaling (Beverly, MA, USA); cyclin D1 and GFP were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal antibodies against caspase-3 and β-actin were respectively purchased from Imgenex (San Diego, CA, USA) and MP Biomedicals (Irvine, CA, USA). The pEGFP-Pin1 expression vector was provided by Prof. Pei-Jung Lu.
Cell culture
CRC cell lines were provided by Prof. YW Cheng and Prof. H Lee's laboratory. All CRC cell lines were cultured in RPMI-1640, supplemented with 10% fetal bovine serum (FBS) and antibiotics. CRL-1459/CCD-18Co (non-malignant human colon cells) was provided by Prof. PJ Lu's laboratory and cultured in minimum essential Eagle's medium, supplemented with 10% FBS and antibiotics.
Cell viability assay
Cell viability was determined by the crystal violet staining method, as described previously [16] . In brief, cells were plated in 96-well dishes at a density of 4000 cells/ml and were treated with DMSO, 17-AAG, NVP-AUY922, BBR, or a combination of NVP-AUY922 and BBR at the indicated concentrations, and viable cells were stained with 0.5% crystal violet in 30% ethanol for 10 min at room temperature for the indicated time. Plates were then washed four times with tap water. After drying, cells were lysed with a 0.1 M sodium citrate solution, and dye uptake was measured at 550 nm using a 96-well plate reader. Cell viability was calculated from the relative dye intensity compared to untreated samples.
Tissue microarray and CRC clinical specimens
A colon adenocarcinoma tissue array was purchased from US Biomax (CO1505, including 50 cases of colon cancer tissues with matched adjacent tissues as the controls). CRC tumor tissues were collected from 192 nonselected patients who underwent surgical resection for CRC at the Department of Surgery, Taipei Medical University Hospital (Taipei, Taiwan). All patients gave informed consent, and the protocol was approved by the IRB Committee before a tissue sample was collected during their planned surgery. The clinical stages and pathologic features of primary tumors were defined according to the criteria of the American Joint Commission on Cancer. All the tissue sections were stained with a standard immunohistochemical (IHC) protocol. Briefly, slides were deparaffinized by serial xylene-ethanol treatment. Antigens were retrieved by boiling in sodium citrate buffer for 10 min. Slides were blocked in 5% normal goat serum for 1 h at room temperature. After blocking, slides were incubated with a primary antibody against Hsp90, CDK4, survivin and Pin1, respectively, followed by a biotinconjugated secondary antibody, polymer-horseradish peroxidase (HRP), and a diaminobenzidine tetrahydroxychloride (DAB) solution. The intensity of staining was scored as follows: 0 point, negative; 1 point, weakly positive; 2 points, moderately positive; or 3 points, strongly positive. The percentage of positive tumor cells (0-100%) was multiplied by the intensity of all proteins staining; therefore, the overall score ranged from 0 to 300. We divided the proteins expression scores (0-300) into two groups: low expression (0-150) and high expression (151-300).
Quantitative reverse-transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from the cell lines with or without drug treatment using a Qiagen RNeasy kit and Qiashredder columns according to the manufacturer's instructions (Qiagen, Valencia, CA, USA). One microgram of total RNA was reverse-transcribed to complementary (c)DNA using a ReactionReady™ First Strand cDNA Synthesis Kit (SABiosciences, Frederick, MD, USA). A quantitative RT-PCR was carried out in an Applied Biosystems StepOnePlus™ Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using an automated baseline and threshold cycle detection. Sequences of specific primers for each gene are listed in Supplementary Table 1. To detect the expression level of miR-296-5p, amplification and detection of specific products were performed with the cycle profile according to the miScript PCR starter kit (Qiagen, Valencia, CA, USA). The relative gene expression level was calculated by comparing the cycle times for each target PCR. The target PCR Ct values were normalized by subtracting the internal control of U6 rRNA Ct value.
Cell-cycle analysis
Cells were treated with or without drugs for 48 h, and a cell-cycle analysis was then performed. The distribution of cell-cycle phases was assayed by PI staining and flow cytometry (FACScan; BD Biosciences, San Jose, CA, USA). Histograms were fit for cell-cycle ratios using ModFit software (Verity Software, Turramurra, NSW, Australia).
Western blot analysis
Cell lines were placed in lysis buffer at 4°C for 1 h. Protein samples were electrophoresed using 8-15% SDS-polyacrylamide gel electrophoresis (PAGE) and performed as previously described [17] .
Human phospho-kinase array
HCT-15 and HT-29 cell lines were analyzed in the panel of phosphorylation profiles of kinases after treatment with DMSO, NVP-AUY922 alone, and the combination of NVP-AUY922 and BBR (human phospho-kinase array, ARY003; R&D Systems). This array specifically screens for relative levels of phosphorylation of 42 individual proteins involved in cellular proliferation and survival. After treatment with DMSO, NVP-AUY922 alone (10 nM), and the combination of NVP-AUY922 (10 nM) and BBR (10 μM), cell lysates were incubated with the membrane. Thereafter, a cocktail of biotinylated detection antibodies, streptavidin-HRP, and chemiluminescent detection reagents was used to detect phosphorylated proteins. Relative expressions of specific phosphorylated proteins were determined following quantification of scanned images by ImageJ compared to NVP-AUY922, the combination of NVP-AUY922 and BBR, and the vehicle.
Connectivity Map (CMap) analysis
CMap (build02, http://www.broad.mit.edu/cmap/) contains more than 7000 expression signatures representing 1309 compounds. Upand downregulated gene groups were simultaneously submitted to CMap for analysis. Compounds with negative connectivity scores, which imply a mode of action by the matched compounds to reverse the expression direction of query genes in CRC, were recorded as potential therapeutic agents for CRC.
Statistical analyses
All observations were confirmed by at least three independent experiments. Results are presented as the mean ± SE. We used onetailed Student's t-tests for all comparison experiments. Survival curves were analyzed using the log-rank Kaplan-Meier method. For drug combination studies, the synergistic effect was assessed by the combination index (CI), according to the method of Chou and Talalay wherein synergism is defined as CI b 1, while antagonism is CI N 1, and an additive effect is considered to be CI = 1 [18] . CI values were calculated using CompuSyn software (ComboSyn, Paramus, NJ, USA). The correlation of levels of miR-296-5p and Pin1 was determined using Pearson's test. A chi-square test was used to compare Hsp90, CDK4, survivin and Pin1 protein expression with clinicopathologic parameters. All statistical analyses were performed using SPSS software (SPSS, Chicago, IL, USA).
Results
Hsp90 inhibitor with a high potential for treating CRC
Several studies used gene expression profiles of CRC tissues to predict a poor prognosis and determine patients at high risk of recurrence [11, 12] . But, there is no comprehensive clinical CRC gene expression profiling of a related application system that specializes in anticancer agents. Hence, we first examined gene expression profiles of CRC patients using data obtained from the GEO DataSet under accession number GSE21815. Gene expression data of 132 samples of laser-microdissected CRC tumors and nine normal colon controls of patients with no colorectal neoplasm were retrieved from the GEO repository. Supplementary Table 2 summarizes the characteristics of the clinical specimens of CRC used in the study. To discover potentially therapeutic compounds through a combination of chemically induced gene expression profiles and gene expression profiles of CRC patients, we performed a CMap analysis. We specifically looked for compounds that had a signature inversely correlated with the CRCspecific signature, and the top 10 drugs identified by the CMap analysis are summarized in Table 1 . The ranking of candidate drugs was established based on inverse connection scores and p values. At the top of that list, the Hsp90 inhibitor, tanespimycin (17-AAG), showed significant negative enrichment. In addition, as shown in Supplementary  Fig. 1 , the CMap analysis revealed that Hsp90 inhibitors, including tanespimycin, geldanamycin, and alvespimycin, represent potential candidates for treating CRC which suggested that Hsp90 may be a good drug target for CRC.
Hsp90 is upregulated in colorectal tumors, and high Hsp90 expression was correlated with a poor prognosis of patients with CRC
The molecular chaperone, Hsp90, plays important roles in the posttranslational maturation and activation of many critical oncogenic client proteins, such as heat shock factor (HSF)-1 and survivin, which are essential for facilitating malignant transformation and increasing the survival, growth, and invasive potential of cancer cells [19] . To clarify gene expression levels of Hsp90 and Hsp90 client proteins in CRC, we analyzed Hsp90, HSF-1, and survivin gene expressions of 132 samples of CRC tumors and nine normal colon controls of patients as mentioned above. As shown in To evaluate the prognostic significance of Hsp90 expression, we analyzed Hsp90 expression levels of CRC with outcomes was available from the CRC Survival Metabase [20] . As shown in Fig. 1C , the expression level of Hsp90 was able to stratify patients by K-means clustering into two subgroups (low-and high-risk groups) which exhibited significant differences (p = 0.0013) in CRC-specific survival according to the Kaplan-Meier survival analysis (Fig. 1D ). These results indicated that Hsp90 expression was upregulated in CRC and was inversely correlated with a CRC patient's prognosis.
The second generation Hsp90 inhibitor, NVP-AUY922, shows therapeutic efficacy in vitro in CRC cell lines
To evaluate the therapeutic efficacy of an Hsp90 inhibitor in CRC cell lines, we first assessed expression levels of Hsp90 and Hsp90 client proteins at the mRNA and protein levels in CRC cell lines by a quantitative (Fig. 2C, right  panel) . It has been demonstrated that NVP-AUY922 inhibits proliferation of various human cancer cell lines in vitro, with an average IC50 of 9 nM [22] . In addition, Ueno et al. [23] shown that lung cancer cells with an IC 50 Fig. 3B ). We finally analyzed the induction of apoptosis after NVP-AUY922 treatment in the HCT-15, HCT116
WT , and HT-29 cell lines using immunoblotting. It was reported that CDK4 is a sensitive client protein to Hsp90 inhibitors [24] . As shown in Fig. 2D , expression of CDK4 was downregulated in the NVP-AUY922-treated HCT-15 and HCT116
WT cell lines. Moreover, NVP-AUY922 increased apoptosis, as assessed by caspase-3 and poly-(ADP ribose) polymerase (PARP) cleavage, in the HCT-15 and HCT116
WT cell lines. However, this phenomenon cannot be observed in HT-29 cells (Fig. 2D) . Taken together, these data indicate that NVP-AUY922 had an antiproliferative effect by inducing apoptosis in the HCT-15 and HCT116 WT cell lines. 
Inhibition of survivin overcomes resistance to NVP-AUY922 in CRC cell lines
It was demonstrated that the Hsp90 inhibitors, geldanamycin and 17-AAG, induced the overexpression of survivin to enhance cell survival and chemotherapy resistance in HT-29 cells [25] . To determine whether treatment with NVP-AUY922 also causes overexpression of survivin in CRC cell lines, we treated CRC cell lines with the Hsp90 inhibitors, 17-AAG and NVP-AUY922, respectively. As expected, the expression of survivin was induced by 17-AAG in the three CRC cell lines (Fig. 3A,  upper panel) . However, upregulation of the survivin protein just robustly increased in NVP-AUY922-treated HT-29 cells (Fig. 3A, bottom  panel) . This result indicated that upregulation of survivin might have contributed to inhibiting apoptosis in NVP-AUY922-treated HT-29 cells. Silencing of survivin was then hypothesized to increase drug sensitivity to NVP-AUY922 in HT-29 cells. To test this hypothesis, HT-29 cells were transfected with a survivin-specific siRNA oligomer (siSurvivin) or scrambled oligomer (control siRNA), followed by cell viability, caspase-3 and PARP cleavage and cell cycle examinations. As shown in Fig. 3B , survivin protein expression levels were significantly reduced in siSurvivin-transfected HT-29 cells. The cell-viability assay revealed that control siRNA-transfected HT-29 cells treated with NVP-AUY922 at the indicated concentration showed no significant reduction in cell viability compared to cells treated with DMSO (Fig. 3C, white  bar) . However, survivin-knockdown groups showed significantly reduced cell viability by~20% in NVP-AUY922-treated HT-29 cells compared to cells treated with DMSO (Fig. 3C, stripped bar) . Moreover, Western blot results revealed that survivin knockdown was more significant at inducing caspase-3 and PARP cleavage in NVP-AUY922-treated HT-29 cells than control siRNA-transfected NVP-AUY922-treated HT-29 cells (Fig. 3D) . Finally, from the flow cytometric analysis, we found that NVP-AUY922-treated HT-29-siSurvivin cells showed an increased apoptotic sub-G 1 population by~11%, compared to DMSO-treated HT-29-siSurvivin cells (Fig. 3E) . Taken together, these results indicate that survivin plays an important role in the sensitivity of CRC cell lines to NVP-AUY922.
BBR enhances the antiproliferative activity of NVP-AUY922 in CRC cell lines
It is well demonstrated that the overexpression of survivin induces resistance to various anticancer therapies such as chemotherapy and radiation therapy in cancer cells [26, 27] . Recent studies indicated that mTOR/p70S6K signaling is the upstream regulator of survivin [28] . It also has shown that targeting mTOR/p70S6K/survivin axis is an attractive strategy in developing therapeutic agents against CRC cells with chemoresistance of Hsp90 inhibitor (see Table 2 in [61] ). Berberine (BBR), an isoquinoline alkaloid traditional herbal medicine, had the potential to inactivate the activity of p70S6K in cystic renal cells [29] . In addition, BBR was demonstrated to inhibit the proliferation of CRC cells [30] . Thus, first, to evaluate the cytotoxic effects of combining NVP-AUY922 and BBR in CRC cells, we compared growth inhibition that resulted from single or combined treatment with these two compounds. As shown in Fig. 4A and B, the effect was greater when the two agents were combined, even at the lowest combined dosage. To determine whether the combination of NVP-AUY922 and BBR in HCT-15 and HT-29 cells resulted in synergistic antiproliferative effects, the combination index (CI) values were calculated with CompuSyn software. CI values are summarized in Supplementary Table 3 ; CI values were b1, indicating that a synergistic antiproliferative effects exist between NVP-AUY922 and BBR in HCT-15 and HT-29 cells. In view of the above-mentioned growth-inhibitory effects, we were interested in understanding the synergistic effect of NVP-AUY922 and BBR in causing CRC cell growth arrest and death. We next examined the effects of the combination of NVP-AUY922 and BBR on apoptosis and the cell cycle distribution in HCT-15 and HT-29 cells. When simultaneously combined, BBR enhanced NVP-AUY922-induced apoptosis and G 2 /M arrest in HCT-15 cells ( Supplementary Fig. 4 ), but only slight changed the sub-G 1 and G 2 /M phases of HT-29 cells (Supplementary Fig. 5 ). In addition, in HCT-15 cells, the combination of NVP-AUY922 and BBR also caused an increase of cells in the S phase and a corresponding decrease of cells in the G 1 phase ( Supplementary Fig. 4) ; this prevented cells from entering the G 2 phase of the cell cycle. In the HT-29 cell line, there was a decrease of cells in the S phase in NVP-AUY922 and BBR combination groups which indicated cell growth inhibition (Supplementary Fig. 5 ). To further characterize the effects of the combination of NVP-AUY922 and BBR, we used Western blotting to analyze expressions of cell cycle proteins and apoptotic markers after treating HCT-15 or HT-29 CRC cells with NVP-AUY922 and BBR. We observed that combination treatment with NVP-AUY922 and BBR significantly decreases survivin expression in two CRC cell lines ( Fig. 4C and D) . In addition, exposure to NVP-AUY922 and BBR significantly decreased cell-cycle progression and slightly increased apoptosis, which was assessed by a decrease in expressions of cellcycle regulatory proteins (cyclin D1 and CDK4) and induction of caspase-3 and PARP cleavage in HCT-15 cells (Fig. 4C) . Surprisingly, the effect of combined treatment with NVP-AUY922 and BBR significantly decreased cell cycle progression in HT-29 cells by decreasing expressions of cyclin D1 and CDK4 (Fig. 4D) . In summary, these data indicate that the antiproliferative effect of the combination of NVP-AUY922 and BBR on CRC cell lines was by simultaneously inducing apoptosis and cell cycle arrest at the S phase in HCT-15 cells, but inhibiting the proliferation rate by inhibiting the S phase in HT-29 cells.
Treatment of CRC lines with NVP-AUY922 plus BBR results in distinct alterations in phospho-kinase activity
To determine the potential molecular mechanisms by which BBR treatment can sensitize CRC cells to NVP-AUY922 and cause CRC cell growth arrest or death, the HCT-15 and HT-29 cell lines were treated with the DMSO control, NVP-AUY922, or NVP-AUY922 plus BBR, and a human phospho-kinase array was performed which contained 42 kinases and two related total proteins. As shown in Fig. 5A , the phospho-kinase array analysis of HCT-15 cells identified several pathways which were significantly downregulated by the combination of NVP-AUY922 and BBR, compared to the DMSO treatment group. These pathways included the mammalian target of rapamycin (mTOR)/ p70S6 kinase pathway, Akt/glycogen synthase kinase-3 α/β (GSK3α/ β) pathway and members of the mitogen-activated protein kinase (MAPK) signaling pathway (c-Jun N-terminal kinases (JNKs)). However, in HT-29 cells, the above-mentioned kinases did not appear to be downregulated by the combination of NVP-AUY922 and BBR (Fig. 5B) . To confirm this observation, results from antibody array studies were confirmed by Western blots. Protein lysates from the DMSO control-, NVP-AUY922-, or NVP-AUY922 plus BBR-treated HCT-15 and HT-29 cells were analyzed using the antibodies described above. As shown in Fig. 5C , treatment of HCT-15 cells with the combination of NVP-AUY922 and BBR resulted in marked reductions of phosphorylated mTOR at Ser2448, phosphorylated p70S6K at Thr389, phosphorylated Akt at Thr308 and Ser473, and phosphorylated GSK3β at Ser9. In contrast, there were no significant changes in the phosphorylation levels of these kinases in HT-29 cells treated with the combination of NVP-AUY922 and BBR (Fig. 5D ), except for the phosphorylation level of mTOR. Collectively, on the basis of the above results, a broad spectrum of kinases involved in regulating cell growth arrest and death were significantly downregulated by the combination of NVP-AUY922 and BBR-treated NVP-AUY922-sensitive HCT-15 cells, not in NVP-AUY922-insensitive HT-29 cells. Previous study showed that peptidyl-prolyl isomerase, Pin1, is a cochaperone in a scaffolding Hsp90 complex which can be destabilized by Hsp90 inhibitors [31] . Moreover, Pin1 is the upstream regulator of β-catenin [32] , and Pin1-β-catenin signaling was shown to regulate cyclin D1 expression in human breast, liver, and colon cancers when Pin1 was overexpressed [33] [34] [35] [36] . In the present study, we found that the combination of NVP-AUY922 and BBR significantly downregulated β-catenin expression levels compared to DMSO-treated HT-29 cells from our human phospho-kinase array results (Fig. 6A) . To confirm the phospho-kinase array results, we investigated the effect of NVP-AUY922 or NVP-AUY922 plus BBR on the expressions of Pin1, β-catenin, and cyclin D1 by a Western blot analysis. Significant decreases in the expressions of these three proteins were observed after NVP-AUY922 plus BBR treatment in HT-29 cells (Fig. 6B, right panel) . Quantification of these three proteins expression showed that it was reduced by about 60-70% of these three proteins in NVP-AUY922 plus BBR-treated HT-29 cells (Fig. 6B, right panel) . In contrast, there was no significant change in the expression level of Pin1-β-catenin-cyclin D1 signaling in HCT-15 cells treated with the combination of NVP-AUY922 and BBR (Fig. 6B, left panel) . More recently, we have reported that microRNA-296-5p (miR-296-5p) was identified to play a tumorsuppressive role by targeting the 3′-UTR of Pin1 mRNA of prostate cancer [37] . In addition, miR-296-5p was recently found to be progressively lost during tumor progression in various cancers, including CRC [38] [39] [40] . To understand the correlation between miR-296-5p and Pin1 in CRC, we first analyzed the expression levels of Pin1 protein and miR-296-5p in CRC cell lines by Western blot and quantitative RT-PCR analysis. As shown in Supplementary Fig. 6A , the Pin1 protein was highly expressed in five CRC cell lines compared with non-cancerous human colon cells CRL-1459. The miR-296-5p expression was then examined in these cell lines, showing that miR-296-5p were clearly downregulated in five CRC cell lines compared with CRL-1459 cells (Supplementary Fig. 6B ). Across all six cell lines tested, we found an inverse correlation between Pin1 protein levels and miR-296-5p (Pearson correlation coefficient [r] = −0.91); however, there was no association between Pin1-mRNA and miR-296-5p ( Supplementary  Fig. 6C and B, Pearson correlation coefficient [r] = 0.48). These results are consistent with our previous study showing that miR-296-5p playing a tumor-suppressive role by targeting Pin1. We further investigated the effect of combination of NVP-AUY922 and BBR on miR-296-5p expression. As shown in Fig. 6C , we found that treatment of HT-29 cells with the combination of NVP-AUY922 and BBR resulted in marked induction in miR-296-5p expression. Although the expression of miR-296-5p was also induced in NVP-AUY922 alone-treated of HCT-15 and HT-29 cell lines, the induction level of miR-296-5p was not high enough to affect the Pin1-β-catenin-cyclin D1 signaling in this two cell lines. Taken together, these results indicated that BBR can enhance the potency of NVP-AUY922 in NVP-AUY922-insensitive HT-29 cells through induced miR-296-5p-mediated suppression of Pin1-β-catenin-cyclin D1 signaling. Next, to further investigate whether overexpression of Pin1 could abolish drugs trigger cell growth inhibition, we performed the rescue experiment by introducing Pin1-expressing plasmid (pEGFP-Pin1) or empty vector in the presence of NVP-AUY922 alone or NVP-AUY922 plus BBR in HCT-15 and HT-29 cells. As shown in Fig. 6D , ectopic GFP-Pin1 expression can abolish NVP-AUY922 plus BBR-mediated induction of miR-296-5p-regulated suppression of the expression of Pin1, β-catenin, and cyclin D1 proteins in HT-29 cells (Fig. 6D, right panel) . As expected, there were no significant changes in the amounts of Pin1, β-catenin, and cyclin D1 proteins in GFP-Pin1-transfected HCT-15 cells in the presence of NVP-AUY922 alone or NVP-AUY922 plus BBR (Fig. 6D, left panel) . Moreover, antigrowth effect of NVP-AUY922 plus BBR was significantly attenuated by ectopic GFP-Pin1 expression of HT-29 cells (Fig. 6E , right panel, lanes 1 and 3of GFP group versus lanes 1 and 3of GFP-Pin1 group). However, this phenomenon cannot be observed in HCT-15 cells (Fig. 6E, left panel) . This result clarifies that NVP-AUY922 plus BBRmediated inhibition cell growth of HT-29 cells can be through miR-296-5p-mediated suppression of Pin1-β-catenin-cyclin D1 signaling, and that overexpression of Pin1 can abolish pre-miR-296-5p-mediated growth suppression of HT-29 cells. Collectively, these results suggested that combination of NVP-AUY922 and BBR could induce miR-296-5p expression and function in NVP-AUY922-insensitive HT-29 cells, as shown by a reduction of Pin1-β-catenin-cyclin D1 signaling pathway, an important oncogenic pathway in CRC.
Hsp90, Hsp90 client proteins and co-chaperone expression in CRC clinical tissues
To understand whether the expression of Hsp90, Hsp90 client proteins and co-chaperone in cell line models were correlated with CRC clinical tissues, the protein expression levels of Hsp90, CDK4, survivin and Pin1 were determined by IHC in 192 specimens of CRC tissues. The association of several clinicopathologic factors with the proteins mentioned above were illustrated in Supplementary Tables 4 to 7. As shown in Supplementary Table 4 , the level of expression of Hsp90 in patients with nodal metastasis was significantly higher than in those with no metastasis (53.2% vs. 27.7%, p b 0.0001). In addition, patients with advanced-stage (stages III and IV) disease had higher Hsp90 expression than patients with early-stage (stages I and II) disease (49.6% vs. 30.7%, p = 0.011). This result is consistent with the previous finding to indicate that the expression of Hsp90 is elevated in progression of CRC [41] . Furthermore, it has been reported that therapeutic selectivity of Hsp90 inhibitors is due to the presence of highly expressed of Hsp90 in malignant cells [42, 43] . Thus, these results offer the evidence in support of our hypothesis that Hsp90 inhibitors represent potential candidates for treating CRC. The association of clinicopathologic factors with Hsp90 client proteins (CDK4 and survivin) indicated that high CDK4 or survivin expression was associated with tumor stages (p = 0.028 for CDK4, p = 0.008 for survivin) (Supplementary Tables 5  and 6 ). In addition, we found that Pin1 was highly expressed in over 50% of CRC tissues, however, no significant association was found between Pin1 expression and clinicopathologic factors (Supplementary Table 7 ). We finally analyzed the correlation of Hsp90, CDK4, survivin and Pin1 expression in the tumor tissue of the CRC patients. As shown in Table 2 , the expression of CDK4 and Pin1 was significantly positively correlated with levels of Hsp90 (p = 0.030 for CDK4; p = 0.049 for Pin1). However, no significant correlation was found between survivin and Hsp90 expression in the tumor tissues of the CRC patients (p = 0.658). Collectively, these results reflect our in vitro results to indicate that simultaneous inhibition of Hsp90-regulated signaling and survivin can enhance the potency of Hsp90 inhibitor in CRC cells.
Discussion
Gene expression data have traditionally been used to identify specific genes or pathways associated with a disease or drug application [44] . More recently, finding 'connections' between gene-disease or disease-drug pairs using the CMap [13] , which aimed to identify if drugs used for one disease can be applied to another, can benefit from this new approach [15, 45] . In this study, we demonstrated the combined approach of microarray gene expression of CRC patients and CMap data mining to discover the mechanisms of action for the second generation Hsp90 inhibitor, NVP-AUY-922, in CRC cells. There are several lines of evidence that support this conclusion which are listed below. First, NVP-AUY922 has significant proapoptotic and antiproliferative effects in CRC cell lines in vitro. Second, NVP-AUY922-induced drug insensitivity can be abolished by gene-specific or pharmaceutical approaches to inhibit survivin expression. Third, the combination treatment of NVP-AUY922-sensitive cells with NVP-AUY922 and BBR significantly downregulated the activities of a broad spectrum of kinases involved in regulating cell growth arrest and death. Fourth, combined treatment of NVP-AUY922-insensitive cells with NVP-AUY922 and BBR caused cell growth arrest through inhibiting CDK4 expression and miR-296-5p-mediated suppression of Pin1-β-catenin-cyclin D1 signaling pathway. Collectively, this study is the first to report that a combination of NVP-AUY922 and BBR has the potential to treat CRC by a gene expression-based chemical genomics approach, and the regulatory mechanisms of the combination of NVP-AUY922 and BBR were identified and are summarized in Supplementary Fig. 7 .
In the present study, we compared gene expression profiles of CRC patients and those of normal colon control patients with no colorectal neoplasm using the CMap. The CMap analysis is based on the expression statuses of hundreds of genes, and not of a single gene. This method has not been applied to CRC patients until now. The use of this method allows identification of some candidate drugs for CRC. Tanespimycin and LY-294002 were the top two compounds with the highest negative connectivity scores in our CMap results (Table 1) . Tanespimycin is an Hsp90 inhibitor with a less-toxic analogue of geldanamycin, and LY294002 was an early PI3 kinase inhibitor. Hsp90 and PI3 kinase are key proteins and drug targets with major roles in controlling cell survival, cell growth, and apoptosis by modulating the activities of a number of pathways [46, 47] . Moreover, Hsp90-client and PI3 kinase-regulated pathways are often activated in CRC [48] . Hence, targeting Hsp90 or PI3 kinase with potent selective inhibitors can result in cancer cell growth inhibition and induction of cancer cell apoptosis. Thus, analyses of gene expression profiles of CRC patients in this study suggested that Hsp90 could be an effective therapeutic drug target.
Currently, more than 13 small molecule inhibitors of Hsp90 are at various stages of preclinical and clinical development [49] . Tanespimycin was the first Hsp90 inhibitor to enter clinical trials [50] . It showed antitumor activity at non-toxic doses in several human tumor xenograft models and has completed phase II clinical trials in a number of cancers [51] [52] [53] [54] [55] . However, it was demonstrated that the Hsp90 inhibitors, geldanamycin and tanespimycin, induced the overexpression of survivin in lung, nasopharyngeal, and colon cancer cell lines and subsequently enhanced cancer cells' anti-drug ability [25] . Moreover, the survivin protein was strongly positive in the cytoplasm of CRC cells of specimens [56] . Our study demonstrated for the first time that targeting Hsp90 with the second generation Hsp90 inhibitor, NVP-AUY922, caused significant upregulation of survivin in HT-29 cells. Specific inhibition of survivin expression in HT-29 cells by siSurvivin enhanced NVP-AUY922-induced caspase-3-dependent apoptosis. This result implied that the combination of a survivin inhibitor and an Hsp90 inhibitor can provide therapeutic benefits to patients of CRC with resistance to Hsp90 inhibitor treatment. It has been demonstrated that BBR has potency to inhibit survivin of CRC cells [57] . In addition, BBR is one of the most important alkaloids and is widely used as an antibacterial and antimalarial drug. In addition, it was also demonstrated that BBR produces no organ toxicity [58] . In the present study, we found that the combination of NVP-AUY922 and BBR significantly inhibited HT-29 cell growth due to cell growth arrest but did not significantly induce activation of apoptosis. The molecular mechanism of the combination of NVP-AUY922 and BBRtriggered HT-29 cell growth arrest was through inhibition of CDK4 expression and induction of miR-296-5p-mediated suppression of the Pin1-β-catenin-cyclin D1 signaling pathway. It was demonstrated that Pin1 binds the phosphorylated Thr34-Pro35 motif of survivin and functions as a positive regulator of the antiapoptotic function of surviving Table 2 The correlation of Hsp90, CDK4, survivin, and Pin1 expression in tumor tissues of CRC. hepatocellular carcinoma [59] . In our study, significant decreases in the expressions of survivin (Fig. 4D ) and Pin1 proteins (Fig. 6B) were found after NVP-AUY922 plus BBR treatment of HT-29 cells, but the downregulation of survivin and Pin1 proteins was not found to enhance apoptosis in drug-treated HT-29 cells. Thus, such expression interactions between survivin and Pin1 in inhibiting apoptosis in CRC cells may account for the chemoresistance of tumors with survivin and Pin1 overexpression.
In conclusion, both Hsp90 and survivin are regarded as oncogenic proteins, and both have been reported to be drug targets. However, existing survivin targeting strategies have only yielded partial positive responses in clinical trials [60] . Our findings provide a model in which BBR can enhances the antiproliferative activity of NVP-AUY922 in CRC cell lines through inhibition of multiple oncogenic signaling pathways. Moreover, combination treatment with NVP-AUY922 and BBR of CRC cells can abolish NVP-AUY922-induced overexpression of survivin in CRC cells. Thus, dual inhibition of Hsp90 and survivin may enhance the potency of Hsp90 inhibitors and overcome drug resistance in cancer cells.
